October 2, 20246:00 PMVirtualJoin the Sickle Cell Consortium & SCDAA for an Educational Session on the FDA & Accelerated Approval, followed the next day by a Community Town Hall with Pfizer Pharmaceuticals.
To provide clarity and address concerns about the voluntary Pfizer withdrawal of Voxelotor (Oxybryta), the Sickle Cell Consortium, in partnership with the Sickle Cell Disease Association of America (SCDAA), will be hosting a two-day virtual Town Hall event via Zoom on October 2nd and 3rd.
Day 1 (October 2nd): A dedicated educational day explaining the FDA's accelerated approval process and what the withdrawal of an accelerated approval drug means for patients and future treatments.
Day 2 (October 3rd): A live Town Hall featuring special guests from Pfizer, who will discuss the decision and answer questions from the sickle cell community.
This open event is a crucial opportunity for patients, caregivers, advocates, and healthcare providers to gain insight and ask questions directly from Pfizer representatives. We encourage all members of the sickle cell community to attend.
Language: English
